—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Beam Therapeutics Inc (BEAM) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Company snapshot — Beam Therapeutics Inc

BEAM in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Beam Therapeutics develops gene-editing medicines that correct disease-causing mutations directly in patients' cells or tissue. Its lead programme targets sickle cell disease using a patient's own stem cells, while other candidates edit liver cells to treat inherited disorders such as alpha-1 antitrypsin deficiency and phenylketonuria. The company also researches an antibody-based conditioning platform meant to replace chemotherapy before stem-cell therapy. It works with Pfizer, Verve Therapeutics and Orbital Therapeutics on separate gene-editing collaborations and is based in Cambridge, Massachusetts.
Where it sits in the stack
Beam sits outside our AI build-out index; it belongs to the Healthcare sector, in the biotechnology sleeve of our universe, specifically gene-editing therapeutics rather than any technology layer.
Who it is priced against
The diary has no set peer group for Beam; the comparison the market draws is with other gene-editing biotechs such as CRISPR Therapeutics, which pursues similar base-editing and cell-therapy approaches.
Why Closelooknet tracks it
Beam holds no seat in our index and carries no Closelooknet score yet; it has not appeared in the diary's quotes. Chart readings currently show the shares well below both moving averages and off their year high.
What the diary watches
Whether trial results or a new collaboration milestone shift sentiment enough to change how the diary reads the stock's current weakness.

Beam Therapeutics Inc (BEAM) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelooknet reading that exists for BEAM, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BEAM on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

How it trades on rate days beta 1.74 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How BEAM has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.74 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Beam Therapeutics Inc moved 1.74% on average · correlation 0.22 · higher than 98% of US names
  • Beta, last 3 months 2.52 more rate-sensitive lately than over the year
  • On the 10 worst bond days −2.43% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.19% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Beam Therapeutics Inc (BEAM)?

Beam Therapeutics Inc trades as BEAM on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is BEAM in a Closelooknet index?

Not currently — Beam Therapeutics Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does BEAM trade against its moving averages?

Mixed moving-average stack: Trades -9.5% vs the 50-day and -15% vs the 200-day average, 36.6% below the 52-week high and +20% off the 52-week low; a death cross printed 10 sessions ago. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

What does Beam Therapeutics Inc do?

Beam Therapeutics develops gene-editing medicines that correct disease-causing mutations directly in patients' cells or tissue. Its lead programme targets sickle cell disease using a patient's own stem cells, while other candidates edit liver cells to treat inherited disorders such as alpha-1 antitrypsin deficiency and phenylketonuria. The company also researches an antibody-based conditioning platform meant to replace chemotherapy before stem-cell therapy. The diary has no set peer group for Beam; the comparison the market draws is with other gene-editing biotechs such as CRISPR Therapeutics, which pursues similar base-editing and cell-therapy approaches.

Where does Beam Therapeutics Inc sit in the AI build-out?

Beam sits outside our AI build-out index; it belongs to the Healthcare sector, in the biotechnology sleeve of our universe, specifically gene-editing therapeutics rather than any technology layer. Beam holds no seat in our index and carries no Closelooknet score yet; it has not appeared in the diary's quotes. Chart readings currently show the shares well below both moving averages and off their year high.

How does Beam Therapeutics Inc trade when bond yields rise?

Over the past year Beam Therapeutics Inc had a beta of 1.74 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 98% of US names. On the 10 sessions in which long bonds fell most it moved −2.43% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for BEAM, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.